Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05620225 · ClinicalTrials.gov registry record · NA
Axon Therapy and Conventional Medical Management for Painful Diabetic Neuropathy Compared to Sham and Conventional Medical Management
A NA study, sponsored by NeuraLace Medical.
- Completed
- Registry status
- NA
- Development phase
- 93
- Enrollment target
NCT05620225 is a NA study that has completed, run by NeuraLace Medical. The registered enrollment target is 93 participants.
The verdict
NCT05620225, a NA study, has completed, sponsored by NeuraLace Medical.
- COMPLETED
- Registry status
- NA
- Development phase
- 93 participants
- Enrollment target
Study Summary
Compare Axon Therapy plus conventional medical management (CMM) to Sham plus CMM in reducing neuropathic pain in patients with painful diabetic neuropathy (PDM).
Interventions
- DEVICE Axon Therapy and CMM
- DEVICE Sham and CMM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2022-12-15 |
| Est. Completion | 2023-11-22 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05620225
The ClinicalTrials.gov registry entry for NCT05620225 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NeuraLace Medical, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Axon Therapy and CMM is the first listed.
NCT05620225 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05620225 about?
NCT05620225 is a clinical study titled "Axon Therapy and Conventional Medical Management for Painful Diabetic Neuropathy Compared to Sham and Conventional Medical Management". Compare Axon Therapy plus conventional medical management (CMM) to Sham plus CMM in reducing neuropathic pain in patients with painful diabetic neuropathy (PDM).
What is the current status of trial NCT05620225?
This trial is currently completed. It is a NA study. The enrollment target is 93 participants. The study started on 2022-12-15. Estimated completion is 2023-11-22.
What interventions are being tested in trial NCT05620225?
The interventions under investigation include: Axon Therapy and CMM (DEVICE), Sham and CMM (DEVICE).
Who is sponsoring clinical trial NCT05620225?
This trial is sponsored by NeuraLace Medical, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.